

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3681817

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
THE HOSPITAL FOR SICK CHILDREN	12/22/2015
UNIVERSITY OF MANITOBA	12/22/2015
RECEIVING PARTY DATA	
Name:	NEW HOPE RESEARCH FOUNDATION, INC.
Street Address:	6 CHARLEY LAKE COURT
City:	NORTH OAKS
State/Country:	MINNESOTA
Postal Code:	55127-6219
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	14660412
PCT Number:	IB2015001208
Application Number:	61954098
CORRESPONDENCE DATA	
Fax Number:	(612)746-4781
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	612-746-4780
Email:	docketing@pdsdlaw.com
Correspondent Name:	PAULY, DEVRIES SMITH & DEFFNER, L.L.C.
Address Line 1:	121 SOUTH 8TH STREET
Address Line 2:	TCF TOWER, SUITE 900
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	386.0001USU1
NAME OF SUBMITTER:	MARK E. DEFFNER
SIGNATURE:	/Mark E. Deffner/
DATE SIGNED:	01/05/2016
Total Attachments: 1	
source=2015_12_22_386_0001USU1_License#page1.tif	

December 22, 2015

Mr. John G. Keimel
President, New Hope Research Foundation
6 Charley Lake Court
North Oaks, Minnesota
55127-6219
U.S.A.

Dear Mr. Keimel,


This is in response to your letter of October 14, 2015.

While we maintain our position set forth in my letter of August 6, 2015, we have - secured written agreement from the University of Manitoba to the grant of rights to New Hope Research Foundation, Inc. (the "Foundation"), on behalf of both the University of Manitoba and The Hospital of Sick Children, pursuant to section 6.3 of the Research Agreement of September 15, 2011 ("Research Agreement").

It is therefore hereby recognized that pursuant to the Research Agreement, The Hospital for Sick Children did grant to the Foundation, on behalf of itself and the University of Manitoba, a perpetual, royalty-free, fully paid-up, unlimited, worldwide and nonexclusive license, including the right to sub-license, to make, have made, use, sell, offer for sale, import, export, lease, donate, reproduce, publish, distribute, create derivative works of, and modify product, methods or services incorporating the invention entitled, "Beta-Hexosaminidase Protein variants and Associated Methods for Treating GM2 Gangliosidosis" invented by Dr. Don Mahuran and Dr. Brian Mark which is described in US Patent Application 61/954,098 filed March 17, 2014, US Patent Application 14/660,412 filed March 17, 2015, and PCT Patent Application PCT/IB2015/001208 filed March 17, 2015 (the "HexM Technology").

Now that this issue has been resolved, we are hopeful that discussions between the Foundation and SickKids' Industry Partnerships & Commercialization office with respect to the further development and commercialization of the HexM Technology can proceed.

Sincerely,



Ramune Pleinys
Executive Director, Research Operations

cc: Arlene Yee, Director, Industry Partnerships & Commercialization, The Hospital for Sick Children
Vishan Sivagnanam, Business Development Officer, The Hospital for Sick Children
Dean Eyler, Attorney, Gray Plant Mooty
Nadine D'Aguiar, Lawyer